Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Colorcon
Farmers Insurance
Moodys
Boehringer Ingelheim
US Army
McKesson
Fuji
Harvard Business School

Generated: December 12, 2018

DrugPatentWatch Database Preview

METHENAMINE HIPPURATE - Generic Drug Details

« Back to Dashboard

What are the generic sources for methenamine hippurate and what is the scope of methenamine hippurate patent protection?

Methenamine hippurate is the generic ingredient in three branded drugs marketed by Us Pharm Holdings, Aurobindo Pharma Ltd, Impax Labs Inc, and Cnty Line Pharms, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for methenamine hippurate. Nine suppliers are listed for this compound.

Medical Subject Heading (MeSH) Categories for METHENAMINE HIPPURATE
Synonyms for METHENAMINE HIPPURATE
1,3,5,7-TETRAAZATRICYCLO[3.3.1.1(3),?]DECANE; 2-(PHENYLFORMAMIDO)ACETIC ACID
1,3,5,7-Tetraazatricyclo[3.3.1.13,7]decane N-Benzoylglycine
5714-73-8
714M738
AC1L2JF7
API0009010
C9H9NO3.C6H12N4
CHEBI:6825
CHEMBL1201104
D00855
EINECS 227-206-5
FT-0671059
Glycine, N-benzoyl, compd. with 1,3,5,7-tetraazatricyclo(3.3.1.1(sup 3,7))decane (1:1)
Haiprex
Hexamethylene tetramine hippurate
Hexamethylenetetramine hippurate
Hexamethylenetetramine monohippurate
Hexamethylenetetramine monohippurate;Hexamethylenetetramine monohippurate
hexamine hippurate
Hippramine
HIPPURIC ACID, compd. with HEXAMETHYLENETETRAMINE (1:1)
Hiprex
Hiprex (TN)
LS-75816
M329791L57
METHENAMINE HIPPURATE (200 MG)
Methenamine hippurate (JAN/USP)
Methenamine hippurate [USAN:USP:INN:BAN]
Methenamine hippurate [USAN]
Methenaminehippurate
N-Benzoylglycine, compound with 1,3,5,7-tetraazatricyclo(3.3.1.13,7)decane (1:1)
PL005986
R-657
SCHEMBL3029
UNII-M329791L57
Viapta

US Patents and Regulatory Information for METHENAMINE HIPPURATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd METHENAMINE HIPPURATE methenamine hippurate TABLET;ORAL 205661-001 Jul 5, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Impax Labs Inc METHENAMINE HIPPURATE methenamine hippurate TABLET;ORAL 076411-001 Jun 20, 2003 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Us Pharm Holdings HIPREX methenamine hippurate TABLET;ORAL 017681-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cnty Line Pharms UREX methenamine hippurate TABLET;ORAL 016151-001 Approved Prior to Jan 1, 1982 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Citi
Mallinckrodt
Harvard Business School
McKinsey
Moodys
Deloitte
QuintilesIMS
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.